Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

4.88USD
15 Dec 2017
Change (% chg)

$0.05 (+1.04%)
Prev Close
$4.83
Open
$4.90
Day's High
$5.05
Day's Low
$4.88
Volume
9,368
Avg. Vol
6,339
52-wk High
$8.18
52-wk Low
$4.17

Chart for

About

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology and advanced tissue care products based upon its... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $22.06
Shares Outstanding(Mil.): 4.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn

* Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language

16 Nov 2017

BRIEF-Sonoma Pharmaceuticals files for mixed shelf of upto $75 mln - SEC filing ‍​

* Sonoma Pharmaceuticals Inc files for mixed shelf of upto $75 million - SEC filing ‍​ Source text: (http://bit.ly/2hfgJ1s) Further company coverage:

09 Nov 2017

BRIEF-Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​

* Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million

09 Nov 2017

BRIEF-Sonoma Pharmaceuticals receives Brazilian approvals

* Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products

31 Oct 2017

BRIEF-Sonoma Pharmaceuticals to commercialize company's new Loyon product in U.S.

* Announced U.S. commercialization of company's new Loyon product

03 Oct 2017

BRIEF-Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

* Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

14 Sep 2017

BRIEF-Sonoma Pharmaceuticals Inc - qtrly‍ net loss per share basic and diluted, continuing operations $0.82​

* Sonoma Pharmaceuticals reports financial results for first quarter of fiscal year 2018

08 Aug 2017

Earnings vs. Estimates